We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.97%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$522M
AUM Growth
-$108M
Cap. Flow
-$65.4M
Cap. Flow %
-12.54%
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.3M
2
MDT icon
Medtronic
MDT
+$16.9M
3
PFE icon
Pfizer
PFE
+$10.7M
4
ELV icon
Elevance Health
ELV
+$7.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$6.07M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$26.6M
2
CELG
Celgene Corp
CELG
+$10.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$8.57M
4
UNH icon
UnitedHealth
UNH
+$8.21M
5
MRK icon
Merck
MRK
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Financials 1.61%
3 Technology 0.16%
4 Energy 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
51
Merck
MRK
$318B
$4.12M 0.79%
73,360
-136,240
-65% -$7.97M
OMCL icon
52
Omnicell
OMCL
$1.68B
$4.02M 0.77%
118,537
– –
GKOS icon
53
Glaukos
GKOS
$10.6B
$3.97M 0.76%
115,800
+110,700
+2,171% +$3.79M
LH icon
54
Labcorp
LH
$25.9B
$3.85M 0.74%
34,920
– –
LIVN icon
55
LivaNova
LIVN
$4.2B
$3.6M 0.69%
+80,000
New +$3.93M
KITE
56
DELISTED
Kite Pharma, Inc.
KITE
$3.59M 0.69%
80,000
-10,000
-11% -$491K
ESPR
57
DELISTED
Esperion Therapeutics
ESPR
$3.44M 0.66%
275,000
+145,000
+112% +$1.73M
ELGX
58
DELISTED
Endologix Inc
ELGX
$3.29M 0.63%
57,500
+14,000
+32% +$1.28M
UHS icon
59
Universal Health Services
UHS
$10.5B
$3.19M 0.61%
30,000
– –
MGNX icon
60
MacroGenics
MGNX
$257M
$3.17M 0.61%
155,000
+15,000
+11% +$378K
NDRM
61
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.17M 0.61%
142,546
-2,000
-1% -$37.4K
CHRS icon
62
Coherus Oncology
CHRS
$196M
$3.13M 0.6%
111,357
-20,000
-15% -$560K
RIGL icon
63
Rigel Pharmaceuticals
RIGL
$750M
$3.05M 0.58%
128,200
-11,800
-8% -$338K
DVA icon
64
DaVita
DVA
$11.7B
$2.89M 0.55%
45,000
-10,000
-18% -$623K
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.71M 0.52%
120,805
– –
TSRO
66
DELISTED
TESARO, Inc.
TSRO
$2.69M 0.52%
20,000
-1,500
-7% -$189K
KERX
67
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.49M 0.48%
425,111
-75,000
-15% -$410K
KYNB
68
Kyntra Bio
KYNB
$29.4M
$2.23M 0.43%
4,160
– –
ADMS
69
DELISTED
Adamas Pharmaceuticals
ADMS
$2.2M 0.42%
130,000
– –
ICPT
70
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.17M 0.42%
20,000
+10,000
+100% +$1.19M
RDUS
71
DELISTED
Radius Health, Inc.
RDUS
$2.09M 0.4%
55,000
-20,000
-27% -$952K
PRGO icon
72
Perrigo
PRGO
$1.78B
$2.08M 0.4%
25,000
-10,000
-29% -$867K
WBA
73
DELISTED
Walgreens Boots Alliance
WBA
$2.07M 0.4%
25,000
-40,000
-62% -$3.31M
ACAD icon
74
Acadia Pharmaceuticals
ACAD
$5.03B
$2.02M 0.39%
70,000
+20,000
+40% +$529K
ILMN icon
75
Illumina
ILMN
$28.4B
$1.92M 0.37%
+15,420
New +$2.08M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rhenman & Partners Asset Management held 119 positions worth $522M, down 17% from $630M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $65.4M in Q4 2016, closing 11 positions and reducing 37 holdings. Its most notable exit was Shire pic, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Gilead Sciences worth $18.6M.

  • Rhenman & Partners Asset Management's largest Q4 2016 buy was Gilead Sciences: 259,894 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016, an estimated $6.07M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $10.4M.
  • Rhenman & Partners Asset Management fully exited Shire pic in Q4 2016, selling an estimated $26.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $522M portfolio in Q4 2016.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 11 in Q4 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 17% quarter-over-quarter to $522M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2016, filed 13 Jan 2017.